LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Accueil・Liste d'Actions・Adaptive Biotechnologies Corp

Search

Adaptive Biotechnologies Corp

Fermé

17.19 -1.15

Résumé

Variation du prix de l'action

24h

Actuel

Min

17.01

Max

18.21

Chiffres clés
By Trading Economics
Revenu	-6.4M -20M
Ventes	-807K 71M
BPA	-0.13
Marge bénéficiaire	-28.24
Employés	624
EBITDA	-7.9M -14M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+18.16% upside

Dividendes
By Dow Jones
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	356M 2.7B
Ouverture précédente	18.34
Clôture précédente	17.19

Adaptive Biotechnologies Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

10 juin 2026, 23:36 UTC

Résultats

Correction to Oracle Reports Higher 4Q Profit Article

10 juin 2026, 23:19 UTC

Actions en Tendance

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10 juin 2026, 23:09 UTC

Principaux Mouvements du Marché

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10 juin 2026, 23:04 UTC

Résultats

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10 juin 2026, 20:44 UTC

Principaux Mouvements du Marché

Caterpillar Raises Quarterly Dividend 8%

10 juin 2026, 23:49 UTC

Acquisitions, Fusions, Rachats

Elliott: Northern Star Should Take No Options Off The Table

10 juin 2026, 23:48 UTC

Acquisitions, Fusions, Rachats

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10 juin 2026, 23:48 UTC

Acquisitions, Fusions, Rachats

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10 juin 2026, 23:47 UTC

Market Talk

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10 juin 2026, 23:47 UTC

Acquisitions, Fusions, Rachats

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10 juin 2026, 23:46 UTC

Acquisitions, Fusions, Rachats

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10 juin 2026, 23:38 UTC

Market Talk

Global Equities Roundup: Market Talk

10 juin 2026, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10 juin 2026, 23:38 UTC

Market Talk

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10 juin 2026, 23:32 UTC

Market Talk

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10 juin 2026, 23:20 UTC

Market Talk

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10 juin 2026, 22:05 UTC

Market Talk

Correction to Bank of Canada Stays on Hold Market Talk

10 juin 2026, 21:57 UTC

Résultats

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 juin 2026, 21:52 UTC

Résultats

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 juin 2026, 21:35 UTC

Résultats

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 juin 2026, 21:22 UTC

Résultats

Oracle Stock Slides on Increased Capital Spending -- WSJ

10 juin 2026, 20:50 UTC

Market Talk

Résultats

Tech, Media & Telecom Roundup: Market Talk

10 juin 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

10 juin 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10 juin 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10 juin 2026, 20:39 UTC

Market Talk

Résultats

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10 juin 2026, 20:34 UTC

Résultats

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 juin 2026, 20:33 UTC

Résultats

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10 juin 2026, 20:33 UTC

Market Talk

Résultats

Global Equities Roundup: Market Talk

10 juin 2026, 20:33 UTC

Market Talk

Résultats

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Comparaison

Variation de prix

Adaptive Biotechnologies Corp prévision

Objectif de Prix

By TipRanks

18.16% hausse

Prévisions sur 12 Mois

Moyen 20.17 USD 18.16%

Haut 22 USD

Bas 18 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

8 ratings

7

Achat

1

Maintien

0

Vente

Basé sur 8 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Autres valeurs du secteur

LLY

Eli Lilly and Co.

1,136.41

JNJ

Johnson and Johnson

238.85

ABBV

AbbVie Inc

225.29

UNH

UnitedHealth Group Inc

407.06

MRK

Merck & Co Inc.

119

Live chat